Investigational drug · Phase 2
ASKG712
Also called: AM712, VIS-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neovascular Age-related Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "ASKG712"
First trial start
2023
Feb 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASKG712", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular Age-related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ASKG712" as an intervention, largest first.
Visara, Inc.Industry
NCT05456828 · 56 participants · Start Feb 10, 2023 · Primary completion Nov 3, 2025
Drug: ASKG712 · For: Neovascular Age-related Macular Degeneration
Sites: Shanghai, China
AffaMed Therapeutics LimitedIndustry
NCT05345769 · 21 participants · Start Apr 28, 2022 · Primary completion Nov 4, 2024
Drug: AM712(ASKG712) · For: Neovascular Age-related Macular Degeneration
Sites: Poway, California; Walnut Creek, California; Lakewood, Colorado · 9 sites in all
Visara, Inc.Industry
NCT05940428 · 10 participants · Start Oct 23, 2023 · Primary completion Oct 21, 2024
Drug: ASKG712 · For: Diabetic Macular Edema
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Neovascular Age-related Macular Degeneration
- OTX-TKIaxitinib implantPhase 33 trials
Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
- IBI302Phase 32 trials
Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- ABP 938Phase 31 trial
Amgen · Neovascular Age-related Macular Degeneration, nAMD
- RRG001Phase 21 trial
Shanghai Refreshgene Technology Co., Ltd. · Neovascular Age-related Macular Degeneration
- SAR402663Phase 21 trial
Sanofi · Neovascular Age-related Macular Degeneration
- SYL1801Phase 21 trial
Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.